


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. **(currently amended):** A pharmaceutical liquid composition comprising ~~as an active ingredient~~ a pyridone derivative represented by the following formula (I):



wherein R¹ is an alkyl group optionally having a substituent selected from the group consisting of a C₁₋₆ lower alkyl group optionally substituted at any of the 3-, 4- or 5-position with a halogen atom, a carboxyl group, an alkoxy carbonyl group, and an amino group and R² is a phenyl group optionally having a substituent selected from the group consisting of a C₁₋₆ lower alkyl group, a halogen atom, a carboxyl group, an alkoxy carbonyl group or an amino group, or a pharmaceutically acceptable salt thereof, and a solvent capable of dissolving said pyridone derivative~~active ingredient~~ in a high-concentration of about 10% to about 25% by weight.

2. **(currently amended):** A pharmaceutical liquid composition according to Claim 1, ~~comprising as the active ingredient wherein the pyridone derivative is a 5-methyl-1-phenyl-2-~~ (1H)-pyridone (Pirfenidone) wherein R¹ is a methyl group at the 5-position and R² is a phenyl group in the formula (I) or a pharmaceutically acceptable salt thereof.

3. **(currently amended):** A pharmaceutical liquid composition according to Claim 1-~~or~~-2, wherein the solvent is a diethylene glycol monoethyl ether.
4. **(original):** A pharmaceutical liquid composition according to Claim 3, wherein the diethylene glycol monoethyl ether has a purity of 99% or higher.
5. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1-~~to~~-4, further comprising a concentrating agent.
6. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1-~~to~~-5, further containing an antioxidant.
7. **(original):** A pharmaceutical liquid composition according to Claim 6, wherein the antioxidant is an α -tocopherol.
8. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1-~~to~~-7, ~~which is suitable to be administered in the form of an~~ orally, percutaneously, nasally or vaginally preparation or as in the form of a spray, patch, inhalant, injection or intravenous drip.
9. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~ Claims 1-~~to~~-8, having the following components:

| <u>Ingredients</u> | <u>% by weight</u> |
|--------------------|--------------------|
| Pirfenidone | 1-25 |
| Diethylene glycol | |

| | |
|---|-------------|
| monoethyl ether | 70-80 |
| Ethanol (95%) | 0-10 |
| Polyvinyl pyrrolidone or hydroxypropyl cellulose | 0-3 |
| Sodium metabisulfite | 0.02-2 |
| Methyl or propyl paraben | 0-0.5 |
| <u>Purified water</u> | <u>0-25</u> |

10. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~
Claims 1-~~to~~8, having the following components:

| | |
|-----------------------|--------------------|
| <u>Ingredients</u> | <u>% by weight</u> |
| Pirfenidone | 10-25 |
| Diethylene glycol | |
| monoethyl ether | 75-80 |
| <u>Purified water</u> | <u>0-10</u> |

11. **(currently amended):** A pharmaceutical liquid composition according to ~~any one of~~
Claims 1-~~to~~8, having the following components:

| | |
|--------------------|--------------------|
| <u>Ingredients</u> | <u>% by weight</u> |
| Pirfenidone | 10-25 |
| Diethylene glycol | |
| monoethyl ether | 75-80 |

Response to Notice of Non-Compliant Amendment under 37 C.F.R. § 1.121
Application No. 10/540,422

Q88273

α -Tocopherol 0.1-0.5

Hydroxypropyl cellulose 0-3

Purified water 0-10 .